LY3541105 for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called LY3541105 to see if it is safe and well-tolerated. The study involves healthy and overweight participants to understand its effects on different body types. Researchers will take blood samples to see how much of the drug gets into the bloodstream and how long it stays there.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This trial is for healthy or overweight men and women who are not able to have children. Men must agree not to donate sperm and use contraception. Participants should have a stable weight for the past 3 months, with BMIs of 18.5-32 kg/m² in Part A or 27-40 kg/m² in Part B.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part A
Single ascending doses of LY3541105 administered subcutaneously
Treatment Part B
Multiple ascending doses of LY3541105 administered subcutaneously
Treatment Part C
Escalating doses of LY3541105 administered subcutaneously
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LY3541105
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University